Leadership Message
Kyowa Kirin upholds the management philosophy of "contributing to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies." As a Japan-based global specialty pharmaceutical company, we are dedicated to utilizing diverse drug discovery technologies, including our unique antibody technologies, to develop groundbreaking new drugs that bring smiles to people's faces.
Our vision for 2030 is to "realize the successful creation and delivery of life-changing value that ultimately makes people smile, as a Japan-based global specialty pharmaceutical company built on a diverse team of experts with a shared passion for innovation."
To achieve this vision, we have defined our focus areas based on the "Story for Vision 2030." These areas include bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, and rare diseases. We are advancing our proprietary antibody technologies and applying modalities like hematopoietic stem cell gene therapy (HSC-GT), while promoting open innovation and partnerships. By identifying unmet medical needs and creating and delivering new drugs and services to meet those needs, and by fostering innovation with patients, we aim to continue creating life-changing value that makes people smile.
And to achieve this, we should first and foremost bring smiles to our employees. In a passage from "Commitment to Life" created at the time of our establishment in 2008, there is a phrase that states, "Not a large company, but with qualities like none other" In other words, the underlying value is not about the size of the company but rather about "making a difference." To invest in our employees’ career growth, development, and overall wellbeing, I believe that their smiles will bring to smiles for those facing illnesses.
Moving forward, we will continue to work as one Kyowa Kirin team to contribute to the health and well-being of people around the world.
Masashi Miyamoto
Representative Director, Chairman & CEO
Abdul Mullick
Representative Director, President & COO
